arrow
J

Junya Kuroda

kyoto prefectural university of medicine
H指数:40
被引数:7,159

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial

慢性粒细胞白血病慢性期老年患者低剂量达沙替尼的长期疗效:DAVLEC II期试验的扩展随访研究

2026-05-280
OA
Non-infectious fever defines a subgroup of patients with poorer survival outcomes in high-risk myelodysplastic syndrome

非感染性发热定义高危骨髓增生异常综合征中预后较差的患者亚群

2026-05-100
PRE
Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum

从关西骨髓瘤论坛对极高龄多发性骨髓瘤治疗的见解

2025-12-310
PRE
Case Report: Immunophenotypically diverse immature patterns; including variable TdT expression; in aggressive B-cell lymphomas and leukemia with MYC rearrangement

病例报告:免疫表型多样的幼稚细胞模式;包括TdT表达的可变性;在伴有MYC重排的侵袭性B细胞淋巴瘤和白血病中

2025-10-090
OAAI
Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study
2025-02-080
OAAI
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients
2024-08-210
PRE
Long-term efficacy and safety of tucidinostat inpatients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results
2024-06-060
OAAI
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203
2024-04-101
OAAI
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study

daratumumab后elotuzumab治疗多发性骨髓瘤的疗效恶化: 一项多中心回顾性研究

2024-03-161
PRE
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan

日本复发/难治性多发性骨髓瘤患者伊扎佐米联合来那度胺-地塞米松的前瞻性、多中心、观察性研究

2023-09-112
OAAI
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
2023-03-295
OAAI